What are the main mechanisms of oncogenic addiction? Joanna Chorostowska (Poland)
| |
Are KRAS mutations druggable? Marina Garassino (Italy)
| |
How does the cancer immunity circle operate (or dysoperate)? Daan Hurkmans (Netherlands), Joachim Aerts (Netherlands)
| |
Session 1: From molecular alterations to cancer immunity in NSCLC - Panel discussion Joanna Chorostowska (Poland), Marina Garassino (Italy), Daan Hurkmans (Netherlands)
| |
Molecular diagnosis for oncogenic addictions Patrick Pauwels (Belgium)
| |
When and how to identify resistance mechanisms to targeted therapies Nicolas Girard (France)
| |
Predictive biomarker of immune checkpoint inhibitors efficacy Thierry Berghmans (Belgium), Luis Paz-Ares (Spain)
| |
Session 2: From molecular target to molecular resistance in NSCLC - Panel discussion Patrick Pauwels (Belgium), Nicolas Girard (France), Luis Paz-Ares (Spain)
| |
Therapeutic strategy for EGFR driven NSCLC Jacques Cadranel (France)
| |
Therapeutic strategy for ALK/ROS driven NSCLC Jan Van Meerbeeck (Belgium)
| |
Therapeutic strategy for other oncogenic drivers David Planchard (France)
| |
Session 3: From molecular addiction to therapeutic strategy in NSCLC - Panel discussion Jacques Cadranel (France), Jan Van Meerbeeck (Belgium), David Planchard (France)
| |
From anti-PD1/L1 inhibitors to new immunotherapies Thierry Berghmans (Belgium)
| |
Which immunotherapy for which patients? Lizza Hendriks (Netherlands)
| |
Combination therapy in the era of immunotherapy Anne-Marie Dingemans (Netherlands)
| |
Session 5: From PD1/PD-L1 monotherapy in selected patients to PD1/PD-L1 combo for all NSCLC - Panel discussion Thierry Berghmans (Belgium), Lizza Hendriks (Netherlands), Anne-Marie Dingemans (Netherlands)
| |